RESULTS FROM SINGLE AGENT TRIALS
K.A. Rogers, P.A. Thompson, J.N. Allan, M. Coleman, et al.
Authors Conclusion from the abstract: Acalabrutinib is tolerable and effective in ibrutinib‐intolerant patients, providing a viable strategy for continuing BTK inhibitor therapy.
S.D. Smith, J. Munoz, D.A. Stevens, S.M. Smith, et al
Authors Conclusion from the abstract: The recommended cerdulatinib Ph2 dose of 30 mg BID was tolerable and efficacious in heavily pretreated r/r FL. The cerdulatinib + rituximab combination appears to be well tolerated, with tumor reductions in all evaluable pts. The safety profile and unique MOA of cerdulatinib support further combination studies in FL.
N. Kalakonda, F. Cavallo, G. Follows, A. Goy, et al.
Authors Conclusion from the abstract: Single agent, oral selinexor demonstrated deep and durable responses in R/R DLBCL (ORR of 27.6% and DOR of 8.4 months). No new safety signals were identified; AEs were managed with dose modification and/or supportive care. Clinical benefit was observed across both GCB and non‐GCB subtypes. These results underscore the potential of selinexor as a novel therapy for R/R DLBCL.
T. Witzig, L. Sokol, W. Kim, F. Foss, et al.
Authors Conclusion from the abstract: Preliminary activity of tipifarnib was observed in PTCL pts, particularly in those with tumors of AITL histology and high CXCL12 expression and enrollment in the CXCL12+ cohort continues.
S.M. Horwitz, F.M. Foss, P. Porcu, A. Moskowitz, et al.
Authors Conclusion from the abstract: DUV 25 or 75 mg BID demonstrated encouraging clinical activity and an acceptable safety profile in RR PTCL, a population in need of new and effective therapies. The ongoing phase 2 PRIMO study dose optimization phase will identify the optimal regimen of DUV monotherapy in RR PTCL and characterize the efficacy and tolerability of DUV in ≈100 pts.
J. Scarisbrick, L.J. Geskin, M. Bagot, D.C. Fisher, et al.
Authors Conclusion from the abstract: This post‐hoc analysis of TTNT, ORR, and compartmental response in stage IB/IIA demonstrates meaningful clinical benefit with MOGA in early stage MF pts previously treated with systemic therapies despite MAVORIC not being powered to determine treatment effect by disease stage.